However, controversial data and some missing links still make difficult to assess the concrete relationship between glycogen deregulation and neuronal damage leading to the fatal symptoms observed in LD patients, such as myoclonic seizures and epilepsy.
INTRODUCTION
1CYG)] [27]. The homology model suggests that the laforin CBM folds into the characteristic two -sheets fold, with the N-and C-termini pointing towards opposite ends of the longest axis of the molecule [28] . Conserved aromatic residues involved in carbohydrate binding are readily observable in the laforin CBM structure: W32, W85 and W99. In the model, these residues form a compact, rigid and surface-exposed hydrophobic site containing inter-ring spacing appropriate for binding to (1,4)-linked glucoses, as is the case for glycoamylase [28] .
Dual specificity phosphatase domain (DSP)
Laforin contains a carboxy-terminal dual specificity phosphatase (DSP) domain. The The endogenous substrate for laforin remained elusive for some time, with several laboratories searching for it by targeted approaches and unbiased screening methods.
Since laforin contains a CBM and the hallmark of LD is aberrant glycogen, multiple laboratories systematically tested proteins involved in glycogen metabolism as possible laforin substrates. In the end, a multi-system approach revealed that laforin directly dephosphorylates glucans instead of proteins involved in glycogen metabolism and these data established laforin as a glucan phosphatase ([23] , [34] , [35] ) (see below).
Although the DSPs share significantly less amino acid conservation than the classical PTPs, they still retain the characteristic αβα PTP fold. In addition, the DSPs share many of the conserved elements first described for the classical PTPs. These enzymes utilize a cysteine residue at the base of the active site cleft within the PTP loop to perform nucleophilic attack of the phosphorous atom of the substrate. An aspartic acid around 30 amino acids N-terminal of the catalytic cysteine acts as the general acid catalyst, enhancing catalysis. A key difference between the classical PTPs and DSPs is that the classical PTPs possess a deeper active site allowing access to only phospho-tyrosine, whereas the DSPs active site is more shallow to accommodate phospho-serine, -threonine, and -tyrosine ([26] , [29] ).
The laforin DSP domain was modeled by comparing it with that of the human DUSP22 phosphatase (PDB: 1WRM; [36]) [27] . This in silico approach suggests that the laforin DSP folds into the characteristic αβα PTP fold consisting of four to five -sheets surrounded by -helices [37] . In this structure, the PTP loop, containing the catalytic cysteine residue (Cys266), and the conserved Asp residue (Asp235) point towards the catalytic groove. Despite these efforts, a crystal structure of laforin is needed to determine how phospho-glucans are bound by the CBM20 and positioned into the laforin DSP active site.
Laforin dimerization
Recombinant laforin purified from bacteria, laforin from cell culture, and laforin from tissue all form dimers ([38] , [39] , [40] ). However, the domain(s) involved in this event, the mechanism(s) driving dimerization, and the biological function of dimerization are poorly understood. One study reported that laforin forms SDS-resistant dimers both in vitro and in vivo [39] . In addition, it was reported that monomeric laforin is inactive and that all of the phosphatase activity is from dimeric laforin [39] . However, recent studies have challenged this finding by demonstrating that monomeric laforin is the most abundant form of the phosphatase under normal reduced conditions, and that laforin phosphatase activity is similar for both monomer and dimer species [33] . The discrepancy is likely due to the oxidative conditions in the experimental methods, since an oxidative environment drives laforin oligomerization and abolishes laforin phosphatase activity. In the study performed by Liu and colleagues they used little to no reducing agents, and for this reason they concluded that monomeric laforin was inactive [39] . Cumulatively, the new data establish that monomeric and dimeric laforin possess similar phosphatase activity and glucan binding ability, and that dimerization is enhanced by increased oxidation [33] . Despite these findings, no biological role was identified for laforin dimers. Dimerization did not affect phosphatase activity, glucan binding, or binding to other known interacting partners. Thus, a role for laforin-331 homodimers is currently unknown. (Fig. 2) . Since laforin is present in the genome of more evolutionarily basal organisms than malin, these results suggest that laforin may perform additional functions independent of malin. It is possible that these functions are conserved from red algae to humans, but these results indicate that at least in lower eukaryotes laforin possesses malinindependent functions, likely glucan dephosphorylation [42] .
Insights from phylogeny

Biological function
Glucan phosphatase activity
A single experiment based on unforeseen findings in the literature revealed that laforin is the founding member of a unique class of phosphatases that dephosphorylate phospho-glucans, the glucan phosphatases [34] . In the 1960s, Yokoi, Sakai and colleagues purified and biochemically characterized LBs from brains of LD patients ([6] , [43] ). They utilized electron-probe microanalysis, by focusing a 1 micron beam of electrons on a LB and they analyzed the wavelength of excited X-rays to determine specific elements within the LB. In a small table as part of a 33 page study, they reported that LBs possess 2-3 fold higher amounts of phosphate compared to glycogen, while other elements were equal in both samples ( [6] , [43] ). While they were unaware of laforin, they did postulate that ester-linked phosphate might explain why amylolytic [47] , [48] , [49] ).
These findings, along with the finding of laforin in protozoan models, provided the impetus to test laforin as a glucan phosphatase. Initially, laforin was shown to dephosphorylate amylopectin from plant starch ([23], [34] ). This result prompted the hypothesis that laforin removes phosphate monoesters from glycogen, allowing glycogen metabolism to proceed normally. In the absence of this activity, glycogen would accumulate more phosphate residues and longer unit chains, due to inhibited branching by the phosphates, and eventually would form an insoluble LB that biochemically resembles amylopectin. The presence of phosphate groups in glycogen was demonstrated back in the 1980s and 1990s ( [50] , [51] ) but up to now, no report on how these phosphates were removed was known. Roach and colleagues confirmed the in vitro dephosphorylation of amylopectin by laforin and also showed that mammalian glycogen was a substrate of this phosphatase [35] . In addition, they demonstrated that glycogen isolated from laforin knockout mice was hyperphosphorylated and developed an abnormal structure ([35], [52] ). Cumulatively, these data established laforin as a glucan phosphatase and provide one mechanism for LB formation. A recent paper from the Roach and DePaoli-Roach labs completed the circle by identifying the source of glycogen phosphate. They found that glycogen synthase incorporates the β-phosphate of UDP-glucose (its substrate) at a rate of 1 phosphate/10,000 glucose moieties as C2-and C3-linked monoesters [53] . Thus, one function for laforin is to prevent the enzymatic error mediated by glycogen synthase leading to the phosphorylation of glycogen. [56] ). In these experiments, the laforin-malin complex ubiquitinates the substrate, decreases the substrate protein levels, and downregulates glycogen levels (Fig. 3) . The role of laforin as an adapter protein is uncoupled from its role as a glucan phosphatase since a catalytically inactive phosphatase mutant (C266S) still recruits malin and targets it to glycogen related enzymes ([55] , [56] ). In addition to PTG and glycogen synthase, one report suggests that malin ubiquitinates glycogen debranching enzyme (GDE/AGL) [57] .
Adapter protein of enzymes involved in glycogen synthesis
This report shows that AGL ubiquitination is increased in a wild-type malin-dependent manner when both proteins are overexpressed. Additionally, these investigators demonstrated that increased levels of cAMP increases the interaction between malin and AGL as measured by co-immunoprecipitation and subcellular localization. New information on the contribution of the laforin-malin complex to glycogen regulation has been reported very recently. Jana and colleagues reported that the laforin-malin complex interacts with neuronatin, an 81 amino acid protein that stimulates glycogenesis. The laforin-malin complex ubiquitinates and promotes the proteasomal degradation of neuronatin; therefore, they proposed that in the presence of an inactive laforin-malin complex, neuronatin accumulates and hyperstimulates glycogen synthesis [58] .
Many of the conclusions regarding glycogen synthase, PTG and other glycogen related proteins were based on cell culture experiments overexpressing malin, laforin and/or the putative substrate. However, multiple laboratories have recently tested these initial findings under more biologically relevant conditions and they have found conflicting results. In contrast with the cell culture data, 3-month old mice lacking laforin did not show increased levels of glycogen synthase or PTG in muscle or brain extracts [52] .
Additionally, two groups found no increase in glycogen synthase, PTG or AGL in malin-deficient mice of 3 to 6 months of age ( [59] , [60] ). However, a third group found dramatically higher levels of glycogen synthase in brain extracts from 11-month old malin-deficient mice compared to wild-type mice [61] .
Although protein ubiquitination was first described as a mechanism for targeting proteins for rapid proteasomal degradation, in recent years other functions of ubiquitination have been delineated that are driven by different types of ubiquitination, e.g. monoubiquitination, multi-versus polyubiquitination, and different chain topology ([62] , [63] ). A recent study reported that the laforinmalin complex produces K63-linked poly-ubiquitin chains in PTG, AMPKα and AMPKβ [64] . These results suggest that the modification introduced by the laforin-malin complex may play a different role from targeting substrates for degradation by the proteasome.
It is possible that under certain circumstances the laforin-malin complex could also promote the formation of K48-linked ubiquitins. This possibility has also been described for parkin, an E3-ubiquitin ligase involved in Parkinson disease that modifies synphilin-1 with both K63-and K48-linked ubiquitin chains [65] . Perhaps this is the reason why the overexpression of laforin and malin promote the proteasomal degradation of PTG [55] . This possibility would reconcile the results obtained in mouse models lacking either laforin or malin, where it has been described that, in spite of having increased levels of glycogen in different tissues (skeletal muscle and brain), there are no differences in either the activity or the protein levels of glycogen synthase or PTG ([35] , [59] , [60] ).
Although, the most recent report on this matter indicates that in the brain of 11 month old mice lacking malin, there is an increase in the levels of the muscle glycogen synthase [61] . These results indicate that the age of the mice may prove important, as the previous studies examined younger mice. These latest results suggest that the laforin-malin complex indeed has a role in vivo in downregulating proteins involved in glycogen homeostasis, but more work is needed to define the mechanism of these events. Supporting the possible role of the laforin-malin complex in the regulation of PTG levels, we found that PTG protein levels were also increased in primary fibroblasts from LD patients [66] . Further bolstering PTG as a bona fide substrate is the ability to recapitulate in vitro ubiquitination of PTG by malin in a laforin-dependent manner using purified components [56] .
Adapter protein in ER-stress and protein clearance
The laforin-malin complex also plays a role in protecting cells from ER-stress conditions. In cell culture models depleted of laforin there is enhanced sensitivity to agents that trigger ER-stress, e.g. thapsigargin and tunicamicin [67] . In laforin-depleted cells, there is a decrease in proteasome activity and an increase in apoptosis upon drug treatment, as compared to control cells [67] . Similar results regarding protein aggregation induced cell death in malin-depleted cells were also reported [68] .
Therefore in the absence of either laforin or malin, there is increased ER-stress response that eventually leads to decreased proteasome function and increased apoptosis, which could be important factors in the development of LD. Strong corroborating evidence for these cell models is that tissue from mice lacking laforin and human LD patients have increased ER stress markers [67] (Fig. 3) .
In addition to loss of laforin resulting in enhanced sensitivity to ER stress, laforin itself seems to contribute to ER stress. Overexpressed laforin is prone to aggregate and these aggregates localize in perinuclear aggresome structures that co-localize with ubiquitin, ER-chaperones, and proteasome subunits [69] . We have also observed co-localization of the autophagy maker p62 with these structures, which suggests that they might be labeled for degradation by autophagy (unpublished results). Laforin aggregation is enhanced when some LD mutant forms of laforin are overexpressed and these aggregates also contribute to increased ER-stress response and increased apoptosis [70] .
The laforin-malin complex has also been implicated in suppressing cytotoxicity produced by the accumulation of misfolded proteins. Ganesh and coworkers overexpressed aggregate prone proteins and demonstrated that laforin-malin in conjunction with HSP70 degrade the aggregates and protect against cytotoxicity [71] .
The laforin-malin complex interacts with misfolded proteins and targets them for degradation by the proteasome. Follow up studies demonstrated that laforin and malin coimmunoprecipitate with the co-chaperone protein CHIP and showed that CHIP stabilizes malin's tertiary structure ( [72] , [73] ).
Finally, laforin has also been described as a positive regulator of autophagy. In both cellular and mouse models lacking laforin there is decreased autophagy. This decrease is due to impaired formation of autophagosomes that leads to decreased content of autophagic vesicles and lower levels of the LC3-II autophagic marker. The molecular basis of this defect is not known, although it seems that in cells lacking laforin the mTOR pathway is overactivated. The changes in autophagy mediated by the absence of laforin may lead to the accumulation of diverse autophagy substrates that would contribute to cell stress and may contribute to cell death [74] (Fig. 3) . Similar defects in autophagy have been recently described in a mouse model lacking malin (Epm2b-/-) [75] . Therefore, autophagy dysfunction is observed in both mouse models of Lafora disease (Epm2a-/-and Emp2b-/-).
Unexpected role: laforin as a tumor suppressor
An unexpected proposed function of laforin is as tumor suppressor. One line of mice expressing SV40 large T antigen and a rearranged T-cell receptor (TCR) developed T cell lymphoma with almost 100% penetrance ( [76] , [77] ). The Zheng laboratory later discovered that in these mice, the TCR disrupted exon 1 of one EPM2A locus and the second locus underwent epigenetic silencing and concluded that laforin could act as a tumor suppressor [77] . The tumor suppression is associated with laforin phosphatase activity, since mice injected with a T lymphoma cell line transduced with a wild type laforin lentiviral vector displayed protection against tumor formation, whereas mice injected with a T-lymphoma cell line transduced with a catalytically inactive laforin (C266S) were not protected [77] . The authors proposed that laforin dephosphorylated pSer9-GSK3β and in the absence of laforin GSK3β would accumulate in its inactive phosphorylated form. As GSK3β is a key regulator of the Wnt signaling, the inactivation of GSK3β would lead to the accumulation of β-catenin inside the nucleus, producing an increase in tumorigenesis [77] . In a follow-up study, the authors reported that laforin negatively regulates the cell cycle through dephosphorylation of GSK3β and its regulation of cyclin D1. Lack of laforin results in increased levels of cyclin D1, which promotes cell cycle progression [78] (Fig. 3) . Despite convincing data demonstrating that laforin suppresses tumor growth in immunocompromised mice, which strongly links laforin with cell cycle progression, the data that supports laforin as a direct GSK3β phosphatase is controversial. Other laboratories tested GSK3β as a laforin substrate using in vivo and in vitro methods during targeted searches for a substrate, before the glucan phosphatase activity was discovered, and did not observe dephosphorylation of GSK3β by laforin ([34], [35] , [79] ). Thus, the link between laforin and tumor suppression in immunocompromised mice remains to be elucidated.
Et alii
Although laforin has been definitively shown to be a glucan phosphatase, multiple studies have also found that laforin directly and/or indirectly interacts with many proteins. Multiple techniques have been utilized to identify possible interaction partners and/or putative substrates and these results are summarized in Table I . Many of these interactions have been discussed above, but, apart from malin, it is unclear at this time what the physiological relevance of some of these interactions may be.
Controlling/Regulating laforin
While the list of interactive proteins and putative roles of laforin continues to expand, to date only four mechanisms have been described on the regulation of laforin. The first discovery of how laforin is regulated was both surprising and perplexing. Using cell culture models we found that malin binds, ubiquitinates, and targets laforin for degradation; and we were able to recapitulate the ubiquitination using purified components in vitro [12] . This result is surprising given that laforin and malin activity are both necessary to inhibit Lafora body formation and LD. However, malin-directed degradation of laforin has been verified in multiple cell culture systems, mouse models, and data from LD patient tissue ([54] , [55] , [59] , [60] , [61] , [67] ).
An additional mechanism regulating laforin protein levels is directly tied to glycogen stores. Roach and coworkers examined mouse models that accumulate higher or lower levels of glycogen and found that laforin protein levels directly correlate with the amount of glycogen [80] . While this link has been described, a mechanism regulating this fluctuation is currently unknown.
Recently, we demonstrated that laforin physically interacts with the AMPKα and AMPKβ subunits of the heterotrimeric AMP-activated protein kinase (AMPK), a key cellular energy sensor [55] . We found that AMPK is a positive regulator of the laforinmalin complex, since the interaction between laforin and malin is enhanced under conditions of AMPK activation [55] . In a follow-up study, we demonstrated that AMPK phosphorylates laforin at Ser25 both in vivo and in vitro [27] . We found that Ser25 is critical for both laforin phosphatase activity and for its ability to interact with established binding partners, e.g. dimerization with itself, malin, and PTG [27]. These results suggest that laforin-Ser25 phosphorylation by AMPK modulates the laforinmalin interaction and provides a means to regulate their role in glycogen metabolism.
However, these data, as with many in the laforin field, are also controversial. Roach and colleagues investigated the levels of PTG in exercised mice, which activate AMPK, and they saw no change in PTG levels [59] . Thus, additional work must be done to determine the role of AMPK in controlling the laforin-malin complex.
The last reported means of regulating laforin activity is via heterodimerization of different splice variants. Ganesh and colleagues characterized different laforin isoforms and found that they display distinct subcellular localization in cell culture ( [15] , [16] ).
In addition, they reported that heterodimerization between truncated isoforms and fulllength laforin results in a phosphatase inactive complex [15] , thus offering a mechanism to regulate laforin function.
LD causes & possible therapeutics
Given the ever-expanding reports of putative laforin functions and laforin-interacting proteins, it is clear that multiple mechanisms drive the progression of Lafora disease.
The different lines of data strongly suggest that glycogen phosphorylation, interactions with glycogen metabolism enzymes, and cellular stresses are all intimately involved in disease progression. However, deciphering the intercalated pathways driving these mechanisms will likely take many more years.
One definitive function of laforin is to remove phosphate from glycogen. Failure to remove covalently attached phosphate from glycogen disrupts glycogen organization and results in LB formation. Laforin clearly functions as a glucan phosphatase, but all of the other proposed functions include some level of controversy. It seems likely that laforin participates in other aspects of glycogen metabolism via functioning as an adapter protein for malin-directed ubiquitination of some glycogen metabolism enzymes. If both of these functions are correct then LB formation would result from either lack of laforin glucan phosphatase activity or lack of laforin's scaffolding ability, with either resulting in LB formation. Once a LB begins to nucleate, it seems probable that the cell would sense a disturbance in its homeostasis and respond with increased unfolded protein response (UPR), ubiquitination, and autophagy (Fig. 3) . Since the reoccurring theme in LD is glycogen, it is not surprising that a link between laforin, energy metabolism, and cell cycle progression has been uncovered. How these pathways impact Lafora disease remains to be determined. Despite a lack of consensus regarding many of the proposed pathways that laforin impacts and the [82] . In the cases where the disease is produced by nonsense mutations in the EPM2A gene (i.e, R241X, the most frequent mutation in Mediterranean countries), treatment with gentamycin or other aminoglycoside antibiotics that produce read-through of stop codons, could be potentially relevant. The use of these antibiotics would be clinically justified for compassionate use of this fatal disorder similar to its use of cystic fibrosis patients ( [1] , [83] , [84] ) In summary, 100 years after the first clinical description of LD, the molecular bases of the disease are beginning to be understood. However, more work is still needed to fully decipher the functions of the two main players in the disease, laforin and malin. With this knowledge, rational therapeutic designs will be proposed that could offer a window of hope to patients suffering from this devastating disease. 
